Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in rapidly progressive ILD secondary to clinically amyopathic dermatomyositis
ChiCTR-IPR-16007958Phase 4Completed
- Sponsor
- Renji Hospital
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pirfenidone in interstitial lung disease (ILD) (2 arms), sponsored by Renji Hospital. Primary endpoints: 6-month survival and 12-month survival. Started Jun 2014; status: completed.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR-IPR-16007958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16007958.